Published in final edited form as:

J Int Neuropsychol Soc. 2012 July ; 18(4): 764–772. doi:10.1017/S1355617712000422.

Neurocognitive Speed and Inconsistency in Parkinson's Disease With and Without Incipient Dementia: An 18-month Prospective Cohort Study

Cindy M. de Frias¹, Roger A. Dixon², and Richard Camicioli^{3,4}

¹School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson, Texas

²Department of Psychology, University of Alberta, Edmonton, Alberta, Canada

³Division of Neurology, University of Alberta, Edmonton, Alberta, Canada

⁴Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada

Abstract

We examined two-wave longitudinal changes in two indicators of neurocognitive speed (i.e., mean rate, intraindividual variability) using one simple and three complex reaction time tasks. Participants included idiopathic Parkinson's disease (PD) patients, with and without incipient dementia, and normal controls. At baseline, there were 45 patients (26 men, 19 women) with idiopathic PD who ranged from 65 to 84 years ($M = 71.3$, $SD = 4.5$) and 47 matched controls (27 men, 20 women) who ranged from 65 to 84 years ($M = 71.4$, $SD = 4.9$). The 18-month longitudinal sample comprised of 74 returning participants (43 controls, 31 PD patients) who had no cognitive impairment or dementia at both waves. Ten of the 31 PD patients returning for Time 3 had dementia or cognitive impairment. These constituted the PD with incipient dementia (PDID) group. Repeated measures analyses of variance showed that the PD and PDID groups were slower over time on the RT tasks whereas the controls improved their performance over time on all tasks. Inconsistency distinguished the two clinical groups (i.e., the PDID group but not the PD group became more inconsistent over time). Changes in neurocognitive speed and inconsistency may be valid clinical markers of PDID.

Keywords

Parkinson's disease; Aging; Intraindividual Variability; Speed; Longitudinal Study; Reaction Time

Intraindividual variability (IIV) is a measure of transient and rapid fluctuations or changes in an individual's performance during brief periods of time (e.g., trial-to-trial). IIV or inconsistency in neurocognitive speed is a known behavioral marker of aging-related cognitive decline (e.g., Fozard, Vercryssen, Reynolds, Hancock & Quilter, 1994; Hultsch, Strauss, Hunter, & MacDonald, 2008; Li, Aggen, Nesselroade, & Baltes, 2001) and greater inconsistency is found in individuals with dementia (e.g., Gorus, De Raedt, Lambert, Lemper, & Mets, 2008; Hultsch, MacDonald, Hunter, Levy-Bencheton, & Strauss, 2000), mild cognitive impairment (e.g., Dixon et al., 2007), following traumatic brain injury (e.g., Collins & Long, 1996; Stuss et al., 1994) and Parkinson's disease (PD) (Burton, Strauss,

Corresponding Author: Cindy M. de Frias, School of Behavioral and Brain Sciences, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080, cdefrias@utdallas.edu, Telephone: (972) 883-4108, Fax: (972) 883-2491.

No conflicts of interest exist.

Hultsch, Moll, & Hunter, 2006; Camicioli, Weiler, de Frias, & Martin, 2008; Crawford, Goodrich, Henderson, & Kennard, 1989; de Frias, Dixon, Fisher, & Camicioli, 2007).

The catecholaminergic modulation model (Li & Lindenberger, 1999; Li, von Oertzen, & Lindenberger, 2006) is a theoretical framework that links inconsistency in performance to the noisier aging brain. The age-related decline in the concentration of catecholamines in the basal ganglia partly accounts for the greater inconsistency in performance in both normal aging and neurological disordered older adults, as compared to younger or healthy controls, respectively. In addition to deterioration of neurotransmitters, other neural correlates of IIV include changes in anatomical, functional, and neuromodulatory characteristics such as smaller corpus callosum area, increased brain activity, variability in BOLD activity, and decreased D2 binding potential (e.g., Anstey et al., 2007; Bellgrove, Hester, & Garavan, 2004; Garrett, Kovacevic, McIntosh, & Grady, 2010; MacDonald, Li, & Bäckman, 2009). In PD patients, cognitive impairment which is nonresponsive to levodopa is associated with cortical and striatal atrophy (Bouchard et al., 2008; Camicioli et al., 2009). These structural changes may indicate the presence of cortical pathology which might affect performance and predict progression to dementia in PD. Performance variability may be a reliable marker of incipient dementia in PD.

Age-related increases in inconsistency on various cognitive tasks have mainly been documented cross-sectionally in healthy and neurologically impaired older adults. Evidence of longitudinal changes in IIV in aging is sparse (see Bielak, Hultsch, Strauss, MacDonald, & Hunter, 2010; Deary & Der, 2005; Fozard et al., 1994; Lövdén, Li, Shing, & Lindenberger, 2007; MacDonald, Hultsch, & Dixon, 2003). However, no known study has examined longitudinal changes in IIV in patients with PD. In our cross-sectional work on PD, we found that two patient groups (treated and untreated PD), showed greater IIV in neurocognitive speed as compared to matched controls (Camicioli et al., 2008; de Frias et al., 2007). de Frias and colleagues (2007) also reported stronger motor-cognitive coupling between inconsistency in neurocognitive speed and executive dysfunction in severe PD patients. Support for the link between tasks that recruit the prefrontal cortex and show IIV derive from functional imaging investigations demonstrating associations between inconsistency and brain activations (Bellgrove et al., 2004; Kelly, Uddin, Biswal, Castellanos, & Milham, 2008). An over-arching goal in the present study is to extend our earlier findings to examine longitudinal (18-month) changes in mean rate and IIV in speed tasks for two groups of PD patients (with and without incipient dementia) and controls.

PD is a common neurodegenerative movement disorder in older adults, and is associated with an increased risk of dementia (Aarsland, Zaccai, & Brayne, 2005). Early and accurate detection of the onset of dementia in PD would facilitate clinical management of the disorder. Known risk factors for PD with incipient dementia (PDID) include older age, male gender, visual hallucinations, and duration of symptoms (Galvin, Pollack, Morris, 2006; Hobson & Meara, 2004). Ventricular enlargement, reflecting cortical atrophy, also occurs in PD patients with incipient dementia (Camicioli et al., 2011). We examine whether concurrent and longitudinal changes in average latency and level of IIV are greater in incipient PDID than (a) PD without dementia or (b) controls. In a related cross-sectional study, Burton et al. (2006) showed that AD patients were more inconsistent than non-demented PD patients and controls. Our study is the first to examine these issues comparatively in PDID and PD (non-demented) patients, as well as controls.

Specifically, we addressed two main issues. First, we compared longitudinal (18-month) changes in mean rate of neurocognitive speed in controls, as well as PD and PDID. Since reduced speed is a common hallmark of parkinsonism, older PD patients would be expected to show increasingly slower performance over time than controls. We expected neurological

complication of incipient dementia to exacerbate this slowing trend over time. Second, we compared longitudinal changes of IIV in neurocognitive speed among the three groups. We hypothesized that (a) PD patients would show an increase in variability compared to controls and (b) greater 18-month longitudinal changes in IIV for those PD patients in an incipient dementia period than for those PD patients who remained stable and non-demented at a later (36-month) follow-up assessment.

Method

Participants

Original sample—At Time (T1), there were 45 PD patients (26 men and 19 women) with a clinical diagnosis of idiopathic PD. All PD participants met UK brain bank criteria for idiopathic PD (Gibb & Lees, 1988), with the exception of allowing patients with symmetrical disease, without tremor and with upgoing plantar responses. All PD patients and controls showed no evidence of clinical dementia and all attained scores above 26/30 on the Mini-Mental Status Examination (MMSE) (Folstein, Folstein, & McHugh, 1975), and 125 or above (cut off score is 123) on the Dementia Rating Scale (DRS) (Brown et al., 1999) at baseline. The PD patients ranged from 65 to 84 years ($M = 71.3$, $SD = 4.5$); the mean level of education was 14.0 years ($SD = 3.0$). The PD patients were recruited from the Movement Disorders Clinic at the University of Alberta or via advertisement in the Parkinson's Society of Alberta newsletter. In addition, at baseline there were age, sex, and education-matched control volunteers (27 men and 20 women). The controls ranged from 65 to 84 years ($M = 71.4$, $SD = 4.9$); the mean level of education was 14.9 years ($SD = 3.6$). The controls were recruited from the University of Alberta General Medicine Clinics and as acquaintances of other volunteers or respondents to local advertisements. Clinical depression was screened and participants were excluded from the study if their depression could not be managed by drug treatment. The study was approved by the University of Alberta Health Ethics review board and performed in accordance with the Helsinki declaration.

Longitudinal samples—We constructed two longitudinal data sets. First, after an 18-month interval, 75 participants returned and completed all relevant tasks at a second wave of testing. Returnees included 43 (of 47) controls and 32 (of 45) PD patients. One of the returning PD patients scored above .5 on the Clinical Dementia Rating scale (CDR) (Morris, 1993) and was excluded from further analyses (leaving 31 dementia-free PD returnees). All PD patients were rated as between Hoehn and Yahr stages I–III (mild to severe). Since there were only three severe cases (Hoehn and Yahr all stage III) and no cases in stage IV, severity was not examined. Regarding attrition, there was no significant group (PD, controls) by longitudinal status (18-month continuers, drop outs) interaction on age or education levels. The second longitudinal data set was constructed as follows. At the subsequent (and final) 36-month follow up, all 31 remaining PD patients returned and 10 were diagnosed with either dementia ($n = 7$) or cognitive impairment ($n = 3$). For our analyses of T1-to-T2 change, we labeled these 10 participants as Parkinson's disease with incipient dementia (PDID). Specifically, because they were diagnosed with significant cognitive impairment or dementia at T3 and were dementia-free at T2, they were incipient dementia PD participants at T2. They were examined in comparison to the remaining PD group and controls at T1 and T2. Although comparable data for controls at T3 are currently unavailable, the presence of potential pre-impairment participants at T2 would produce more conservative tests of our hypotheses.

Assessment

All participants were examined by a neurologist with expertise in aging and PD. The participant and an informant were independently interviewed at each time of measurement

to determine if cognitive impairment was present. The assessment of cognitive impairment was based on consensus from a CDR interview by the physician (with the patient) and a trained research assistant (with an informant and reviewed by the physician) complemented by formal MMSE, Frontal Assessment Battery (FAB; Dubois, Slachevsky, Litvan, & Pillon, 2000), and DRS assessment. Exclusion criteria at baseline included the presence of an unstable medical illness (e.g., active or recent cancer, symptomatic coronary artery disease, renal failure), an illness (other than PD) that could affect thinking or memory (e.g., symptomatic chronic pulmonary disease, epilepsy), or medications that could directly affect cognition (e.g., centrally acting anti-cholinergic medications). General health was graded using the Cumulative Illness Rating Scale (CIRS; Parmelee, Thuras, Katz, & Lawton, 1995). The Hachinski Ischemic Score was used to rate risk factors for vascular dementia (Rosen, Terry, Fuld, Katzman, & Peck, 1980). Severity of cognitive impairment was graded using the CDR (Morris, 1993). Motor function was assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) (Gancher, 1997) and the Hoehn and Yahr staging (Hoehn & Yahr, 1967). Additional assessments included the MMSE (Folstein et al., 1975), the FAB, the DRS (Brown et al., 1999), the National Adult Reading Test-Revised (NART-R) (Blair & Spreen, 1989), and the Geriatric Depression Scale (GDS; 15-item screening version) (Yesavage, 1988). All participants had blood tests to rule out reversible causes of cognitive impairment, including a complete blood count, glucose, urea nitrogen, creatinine, electrolytes, liver enzymes, thyroid stimulating hormone, vitamin B12 and folate levels at baseline. All participants with PD were examined in the *on* state of the dosing interval (i.e., when medication was effective, one to three hours after taking their medication). Because of age and practical concerns (e.g., frailty, ability to tolerate withdrawal) and the desire to examine best cognitive function, patients were not examined in the *off* state. Rather, patients retrospectively rated their *on* and *off* symptoms using the activities of daily living UPDRS-II scale (Goetz, LeWitt, & Weidenman, 2003).

Dementia, which was defined as cognitive impairment in two domains with functional impairment due to cognitive decline, was diagnosed based on both patient assessment and informant report, but did not necessitate memory impairment (i.e., modified from the DSM-IV which was available at the time of study inception). In addition, dementia was diagnosed if patients declined cognitively across two waves as follows: (a) in two or more domains on the CDR, (b) 3 points on the modified MMSE, or 6 points on the DRS (version 2) (i.e., greater than 1 SD change). These values are beyond what would have been expected on the basis of the reliability of the instruments. In addition, the operationalization of PDID is supported by neuroimaging data (Camicioli et al., 2011). That is, the group with PDID showed the greatest atrophy of grey matter relative to PD and controls, which supported the notion that PDID are undergoing brain degeneration. Participants were grouped together in the incipient dementia (PDID) group for T1 and T2 analyses if they had significant cognitive decline or dementia at T3.

Measures and Procedure

We used tasks, measures, and procedures adapted from previous research (Camicioli et al., 2008; Dixon et al., 2007; de Frias et al., 2007).

Reaction Time Tasks

Simple reaction time (SRT) and three two-choice reaction time (CRT-2, CRT-4, and CRT-8) tasks were administered. The instructions emphasized speed of performance. Participants responded to stimuli by pressing keys on a custom designed response console. Responses were recorded in ms. In the SRT task, participants were presented with a warning stimulus (III) followed by a signal stimulus (+) in the middle of the screen. Participants were instructed to press a key with their preferred hand as quickly as possible when the signal

stimulus appeared. A total of 50 test trials were administered with 10 randomly arranged trials presented at each of the five intervals separating the warning and signal stimuli (500, 625, 750, 875, and 1,000 ms). The measures used were the latencies of the 50 test trials. For the three CRT tasks, a 3×3 grid matching the arrangement of keys on the response console was displayed on the screen. This array was used to instrument two-, four-, and eight-choice RT trials. The center square, corresponding to the center key in the response keypad, served as the home key for the participant's preferred forefinger. Each block of 10 trials required the participant to attend to two, four, or eight squares. A warning stimulus was presented, followed (after a delay of 1000 ms) by the appropriate two-, four-, or eight-square matrix. Twenty trials were administered at each level of choice. The measures used were the latencies of all trials averaged across conditions.

Data Preparation

Outliers were trimmed to missing as extremely slow or fast responses might reflect errors (e.g., accidental key press, task interruption). A lower bound for legitimate responses as based on prior research (de Frias et al., 2007) was set for each task at 150 ms. An upper bound was based on computing the mean and standard deviation separately for each of the groups and dropping any trials exceeding the mean by three or more standard deviations. The number of trials dropped across the entire Persons X Trials data matrix was small (approximately 2%). Missing values were imputed for the outlier trials using a regression procedure in which missing value estimates were based on the relationships among responses across trials. Missing values were imputed using data from all available individuals and trials. Dropping outliers and imputing missing data reduces variability thereby providing a conservative approach to examining this issue.

IIV was indexed by computing the intraindividual standard deviation (ISD), a method used in previous research (Dixon et al., 2007; de Frias et al., 2007). The ISD was computed separately across each task to examine inconsistency. Group differences in average level of performance, and also systematic changes over time (trials) associated with practice represent potential confounds for the analysis of IIV. For example, greater IIV in PD patients than normal older adults as evidenced by an ISD computed on raw scores may reflect the fact that PD patients are on average slower than normal aging adults. To control for these potential confounds, we partialled out the effects associated with group and trials and their interaction from the data before computing ISDs. Specifically, we restructured raw latency trials for each speed measure into a person-trial data matrix and separately regressed on (patient-control status) group and trial, and their higher order interactions. This procedure produced residual scores that were independent of group differences in speed or accuracy of performance and systematic variation attributed to practice effects. These purified z-scores were then converted to T-scores (with a score of 50 as the average for the sample), allowing for comparisons between the size of scores between groups. Raw mean RT and standard deviation values (in ms) for each group by wave of measurement is presented in Table 1.

Alpha levels of $p < .05$ were specified as the threshold to indicate statistical significance.

Results

Preliminary Analyses

Table 2 shows the cognitive impairment and health status of the PD patients and controls who participated over the 18-month period. There were no significant group differences over time on either status.

A group (3: PDID, PD, controls) by task complexity (3: CRT2, CRT4, CRT8) by time (2: T1, T2) repeated measures ANOVA was conducted on the CRT average rate and IIV scores.

There were no significant interactions with task therefore subsequent analyses for task were based on two complexity levels (simple, complex) by combining the CRT2, CRT4, and CRT8 scores for average rate and IIV, separately.

Issue 1: Longitudinal Change in Rate of Response Speed—A group (3: PDID, PD, controls) by task complexity (2: simple, complex) by time (2: T1, T2) repeated measures MANOVA was conducted on the mean latency scores. Only significant interactions are reported. The time by group interaction was significant, $F(2,71) = 24.28$, $p < .001$, $\eta^2 = .41$. Based on the 95% confidence interval around the means, the controls became significantly faster over time overall (T1 $M = 48.15$, $SE = .67$; T2 $M = 46.40$, $SE = .76$), whereas the PD (T1 $M = 47.45$, $SE = .92$; T2 $M = 51.08$, $SE = 1.04$) and PDID (T1 $M = 51.72$, $SE = 1.12$; T2 $M = 58.04$, $SE = 1.28$) groups became slower over time overall. (See Figure 1.) The task by group interaction was significant, $F(2,71) = 9.24$, $p < .001$, $\eta^2 = .21$. Based on the 95% confidence interval around the means, task complexity did not moderate performance for controls (simple $M = 47.40$, $SE = .86$; complex $M = 47.15$, $SE = .64$). However, the PD group (simple $M = 50.67$, $SE = 1.18$; complex $M = 47.85$, $SE = .87$) was less affected by task complexity (appearing more like controls) than the PDID group (simple $M = 52.54$, $SE = 1.44$; complex $M = 57.22$, $SE = 1.06$). (See Figure 2.) The results were unchanged covarying for age and gender.

In order to check the potential effect of overall motor impairment (UPDRS-III) as measured at baseline in accounting for the two significant interactions, we computed a repeated measures multivariate analysis of covariance (MANCOVA) for the PD and PDID groups only. The results indicated that after controlling for UPDRS-III at baseline, the group by task interaction remained significant ($p < .01$) but the time interaction did not ($p = .28$).

A logistic regression model was conducted with the two 18-month change (using difference scores) in mean rate scores in the same model. All three combinations of group membership were then compared (i.e., controls vs. PD patients, controls vs. PDID patients, and PD vs. PDID patients) in three separate models (see Table 3). Change in mean rate in CRT was a significant predictor of group membership between PDID vs. controls: ($\text{Exp } B = 2.32$; 95% CI = 1.23–4.35 (sensitivity = 71%; specificity = 97%). The positive predictive value (PPV) was 91% and the negative predictive value (NPV) was 90%. Change in mean rate in CRT was also a significant predictor of group membership between PD vs. controls: ($\text{Exp } B = 4.01$; 95% CI = 1.82–8.8 (sensitivity = 95%; specificity = 97%). The PPV is 95% and the NPV is 97%. (See Table 3.) No other effects were significant.

ROC analyses were conducted by generating the predicted probabilities associated with each group comparison from the logistic regression model. The area under the ROC curve (AUC) comparing PD and controls was .71 ($p < .01$, 95% CI = .55, .86) for SRT, and .98 ($p < .001$, 95% CI = .95, 1.00) for CRT. The AUC comparing PDID and controls was .76 ($p < .01$, 95% CI = .59, .92) for SRT, and .96 ($p < .001$, 95% CI = .91, 1.00) for CRT. The AUC comparing PDID and PD groups was .59 ($p > .05$, 95% CI = .39, .79) for SRT, and .63 ($p > .05$, 95% CI = .40, .85) for CRT.

Issue 2: Longitudinal Change in Inconsistency—A group (3) by task complexity (2) by time (2) repeated measures MANOVA was conducted on the mean ISD scores. Similar to Issue 1 above, only significant interactions will be presented. The time by group interaction was significant, $F(2,71) = 6.03$, $p < .01$, $\eta^2 = .15$. Based on the 95% confidence interval around the means, the PDID patients (T1 $M = 7.58$, $SE = .37$; T2 $M = 9.22$, $SE = .45$) were more inconsistent over time, whereas the controls (T1 $M = 6.12$, $SE = .22$; T2 $M = 6.09$, $SE = .27$) and PD patients (T1 $M = 6.55$, $SE = .30$; T2 $M = 7.14$, $SE = .37$) did not change in inconsistency over time. (See Figure 3.) The task by group interaction was significant,

$F(2,71) = 3.79, p < .05, \eta^2 = .10$. Based on the 95% confidence interval around the means, the PD patients' level of inconsistency (simple $M = 6.77, SE = .32$; complex $M = 6.92, SE = .38$) was unaffected by task complexity. However, the controls' (simple $M = 6.42, SE = .24$; complex $M = 5.79, SE = .28$) and the PDID patients' (simple $M = 7.98, SE = .40$; complex $M = 8.82, SE = .46$) level of inconsistency were more affected by task complexity. (See Figure 4.)

A repeated measures MANCOVA was conducted for the PD and PDID patients only, to examine the potential effect of overall motor impairment (UPDRS-III) at baseline in accounting for the two significant interaction effects. Neither interaction was significant after controlling for overall motor impairment, indicating that task performance is related to overall progression of PD.

A logistic regression model was conducted with the two 18-month change (using difference scores) in IIV scores in the same model. As before, all three combinations of group membership were then compared in three separate models. Change in IIV in SRT ($\text{Exp } \beta = 1.38; 95\% \text{ CI} = 1.05\text{--}1.83$) was a significant predictor of group membership between PDID and controls. The sensitivity was 24% and the specificity was 92%. The PPV was 63% and the NPV was 73%. (See Table 3.) No other effects were significant.

ROC analyses were conducted by generating the predicted probabilities associated with each group comparison from the logistic regression model. The area under the ROC curve (AUC) comparing PD and controls was .65 ($p > .05, 95\% \text{ CI} = .50, .79$) for SRT, and .52 ($p > .05, 95\% \text{ CI} = .35, .68$) for CRT. The AUC comparing PDID and controls was .69 ($p < .05, 95\% \text{ CI} = .53, .85$) for SRT, and .66 ($p > .05, 95\% \text{ CI} = .47, .85$) for CRT. The AUC comparing PDID and PD groups was .57 ($p > .05, 95\% \text{ CI} = .36, .77$) for SRT, and .62 ($p > .05, 95\% \text{ CI} = .42, .81$) for CRT.

Discussion

We examined longitudinal (2-wave, 18-month) changes in two indicators of neurocognitive speed performance (average rate and IIV) in non-demented PD patients, controls, and PD patients with incipient dementia (PDID). As supported by (a) our previous inconsistency results with PD patients (de Frias et al., 2007), (b) theoretical models (Li & Lindenberger, 1999) applied to PD, and (c) previous studies IIV in normal aging and cognitive impairment, we predicted both relatively greater slowing and inconsistency over time for the PDID group, followed by the PD and control groups. We addressed two main research issues. First, we examined whether the three groups had similar two-wave trajectories of mean rate (speed) performance. We found that the controls became faster over time, perhaps due to practice effects, whereas both the PD and PDID groups became slower. Interestingly, recent research shows that practice effects may be an early marker of incipient cognitive decline (Cooper et al., 2004; Duff et al., 2007; Suchy, Kraybill, & Franchow, 2011). The apparent reduced or lack of practice effects in our study for PD or PDID patients may be attributed to a compromised ability to benefit from practice, at least at 18-month intervals when motor declines may cancel potential practice-related improvements. The lack of learning effect could reflect dopaminergic loss as seen in all PD patients. In addition, greater novelty effects on a motor task was found among older adult cognitive decliners relative to nondecliners (Suchy et al., 2011), likely due to vulnerable cognitive reserves. We also found that the groups differed in how task complexity affected their performance. Task complexity did not moderate the average rate of controls, but did affect the performance of the PD and PDID groups. To address the second main issue, we examined the three groups on inconsistency. Our 18-month longitudinal data showed that the PDID patients became more inconsistent over time, whereas the stable PD patients and controls remained at baseline levels of

inconsistency. Greater task complexity moderated inconsistency, such that the groups become more different from each other with task complexity. Within groups, the controls were less inconsistent, the PD remained unaffected, and the PDID group became more inconsistent with advancing complexity.

To explore these results further, we conducted several follow-up analyses. First, we examined the potential effect of overall motor impairment (UPDRS-III) at baseline in accounting for the significant group by time interaction effects. The group by time interaction for average rate was not significant, along with the interactions for inconsistency after covarying for UPDRS-III at baseline and these findings were also found using UPDRS-III at T3. Change in average rate and inconsistency may have been partly accounted for by dopaminergic deficits in motor pathways and disease progression. Second, we compared the relative effectiveness of IIV and mean rate in distinguishing change between PD, PDID, and controls. Examining ROC models, we found that the predictive validity of change in mean rate or IIV on membership into PD vs. PDID groups was not supported by the AUC. However, the logistic regression analyses showed that the PDID and PD groups were more likely to show slower mean rate of performance (in CRT) over time than the controls. The ability to differentiate the controls from PD and PDID groups was further supported by the ROC model. The logistic regression analyses showed that the PDID group was more likely to show greater inconsistency (in SRT) over time than the controls, and the ability to differentiate these two groups was further supported by the AUC.

Overall, these results extend related earlier work. For example, we found that PD patients (both treated and untreated groups) were slower and more inconsistent than controls, and that PD disease severity was a moderator of IIV (Camicioli et al., 2008; de Frias et al., 2007). The present study extends these findings by showing that changes in mean rate and inconsistency are greatest in PD patients with incipient dementia. Clinically, this implies that neurocognitive speed deficits may be early markers of PDID, perhaps distinguishing those with preclinical dementia from those who remain stable in non-demented status. Theoretically, these results call attention to the well-known fact that PD patients may differentially develop early signs of dementia, and even common concurrent assessment techniques may not be sensitive to preclinical changes. Accordingly, in single-occasion studies, some dementia-free PD patients may in fact be in the very early—and difficult to detect—preclinical phases, thus affecting the overall group average performance on other assessment tests. For both clinical and research reasons, it is important to identify those PD patients with incipient dementia: Systematic assessment of neurocognitive speed may provide important markers. Is there a difference in effectiveness between the two markers we tested? Our study shows that change in IIV is a more sensitive marker compared to change in mean rate in differentiating the longitudinal profiles of PDID from PD in the preclinical phase. One clinical implication of these results is that individuals with PDID who show greater inconsistency over time may be especially targeted for selection into cognitive-enhancing therapies.

Our findings also extend those of cross-sectional studies showing slower speed and greater inconsistency in aging groups with increased neuropathology, but not for groups with somatic or peripheral disease (Hultsch et al., 2000; Whitehead, Dixon, Hultsch, & MacDonald, 2011). For example, recent studies have reported exaggerated inconsistency in neurocognitive and attention performance in older individuals with mild cognitive impairment (Dixon et al., 2007) and mild dementia (Duchek et al., 2009; Gorus et al., 2008). A study by Burton et al. (2006) reported greater slowness and IIV for a PD group than controls, but the AD group performed worse in both aspects of neurocognitive speed. Notably, all these studies show that IIV discriminates between normal aging and early-to-severe cognitive impairment. The present results supplement this perspective by showing

that changes in inconsistency and general slowness are especially marked in PD patients with incipient dementia, as compared even to parallel PD patients with no incipient dementia. The pathology of advanced PD is marked by symptoms that are not responsive to dopaminergic therapy, such as dementia. The mechanisms underlying greater IIV in PDID may be due to a decrease in catecholamines (Li & Lindenberger, 1999), cholinergic deficits (Klein et al., 2010) or cortical pathology (Camicioli et al., 2011).

Several limitations of the present study can be noted. First, most of our PD patients were using dopaminergic medications for treatment of symptoms, but our previous research (Camicioli et al., 2008) shows that untreated PD patients were also more inconsistent in neurocognitive speed than controls. All participants with PD were tested in the *on* state of the dosing interval, a period noted for improved motor functioning. Both medication use and time of testing may serve to minimize potential differences between patients and controls. Second, our PD group size became smaller over time; however, reliable group differences and changes were detected. Third, a younger PD group was not included in the study design. Such a comparison group would be useful to examine whether greater IIV is specific to aging and PD or a function of disease pathology. Fourth, errors were not collected to examine error rates across groups, leaving the possibility that some participant groups may have expressed speed/accuracy trade-offs, making them appear faster. Fifth, our measures included visual reaction time tasks and therefore our results may not generalize to other modalities (e.g., auditory reaction time tasks). Sixth, as T3 data for controls is not currently available, 36-month trajectories cannot be examined. Conceivably, some controls may have declined by T3, but any pre-impairment condition would provide for a more conservative test of the hypotheses of group differences.

Several strengths of the paper can also be noted. First, the three-wave longitudinal design permitted a unique test of non-demented PD patients compared to PDID patients. Such a preclinical group is an important addition to the literature. Second, our study demonstrates the clinical utility of neurocognitive inconsistency as a potential clinical symptom for the early identification of incipient dementia in PD. Third, all participants were well characterized and strict exclusionary criteria were applied. Although some studies have begun to examine longitudinal changes in neurocognitive performance in healthy control samples (e.g., Bielak et al., 2010; Lövdén, Li, Shing, & Lindenberger, 2007; MacDonald et al., 2003), ours is the first to date to focus on longitudinal changes in neurocognitive speed and inconsistency in PD and PDID groups.

In conclusion, our study shows that longitudinal profiles of both mean rate of neurocognitive speed and IIV distinguish between PDID and healthy aging, and IIV distinguishes PD and PDID (incipient dementia). Future research may examine the neural correlates of changes in mean rate and IIV to illuminate the mechanisms underlying the bifurcation between those PD patients who become demented from those who remain dementia-free.

Acknowledgments

Richard Camicioli was supported by an operating grant from the Canadian Institutes of Health Research (CIHR) (MOP-67132). Roger Dixon was supported by grants from the U.S. National Institute on Aging (R37 AG008235) and the Canada Research Chairs program. We thank Nancy Fisher for data collection of the RT tasks, which were adopted from the Victoria Longitudinal Study. The information in this manuscript and the manuscript itself has never been published either electronically or in print.

References

- Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies in dementia in Parkinson's disease. *Movements Disorders*. 2005; 20:1255–1263.

- Anstey KJ, Mack HA, Christensen H, Li S-C, Reglade-Meslin C, Maller J, Sachdev P. Corpus callosum size, reaction time speed and variability in mild cognitive disorders and in normative sample. *Neuropsychologia*. 2007; 45:1911–1920. [PubMed: 17240409]
- Bielak AAM, Hultsch DF, Strauss E, MacDonald SWS, Hunter MA. Intraindividual variability is related to cognitive change in older adults: Evidence for within-person coupling. *Psychology and Aging*. 2010; 25:575–586. [PubMed: 20853965]
- Bellgrove MA, Hester R, Garavan H. The functional neuroanatomical correlates of response variability: Evidence from a response inhibition task. *Neuropsychologia*. 2004; 42:1910–1916. [PubMed: 15381021]
- Blair JR, Spreen O. Predicting premorbid IQ: A revision of the National Adult Reading Test. *The Clinical Neuropsychologist*. 1989; 3:129–136.
- Brown GG, Rahill AA, Gorell JM, McDonald C, Brown SJ, Sillanpaa M. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease. *Journal of Geriatric Psychiatry and Neurology*. 1999; 12:180–188. [PubMed: 10616865]
- Burton CL, Strauss E, Hultsch DF, Moll A, Hunter MA. Intraindividual variability as a marker of neurological dysfunction: A comparison of Alzheimer's Disease and Parkinson's Disease. *Journal of Clinical and Experimental Neuropsychology*. 2006; 28:67–83. [PubMed: 16448976]
- Camicioli R, Gee M, Bouchard TP, Fisher NJ, Hanstock CC, Emery DJ, Martin WR. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. *Parkinsonism Related Disorders*. 2009; 15:187–195. [PubMed: 18573676]
- Camicioli RC, Weiler M, de Frias CM, Martin WRW. Early, untreated Parkinson's disease patients show reaction time variability. *Neuroscience Letters*. 2008; 441:77–80. [PubMed: 18597939]
- Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C, Emery D, Martin WRW. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. *Movement Disorders*. 2011; 26:1443–50. [PubMed: 21442661]
- Collins LF, Long CJ. Visual reaction time and its relationship to neuropsychological test performance. *Archives of Clinical Neuropsychology*. 1996; 11:613–623. [PubMed: 14588445]
- Cooper DB, Lacritz LH, Weiner MF, Rosenberg RN, Cullum CM. Category fluency in mild cognitive impairment: Reduced effect of practice in test-retest conditions. *Alzheimer Disease and Associated Disorders*. 2004; 18:120–122. [PubMed: 15494616]
- Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in Parkinson's disease: Manual key presses and saccadic eye movements to regular stimulus events. *Journal of Neurology, Neurosurgery, and Psychiatry*. 1989; 52:1033–1042.
- Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. *Neurology*. 2002; 59:1042–1046. [PubMed: 12370459]
- Deary IJ, Der G. Reaction time, age, and cognitive ability: Longitudinal findings from age 16 to 63 years in representative population samples. *Aging, Neuropsychology, and Cognition*. 2005; 12:187–215.
- Dixon RA, Garrett DD, Lentz TL, MacDonald SWS, Strauss E, Hultsch DF. Neurocognitive markers of cognitive impairment: Exploring the roles of speed and inconsistency. *Neuropsychology*. 2007; 21:381–399. [PubMed: 17484601]
- Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: A Frontal Assessment Battery at bedside. *Neurology*. 2000; 55:1621–1626. [PubMed: 11113214]
- Duchek JM, Balota DA, Tse C-S, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's Disease. *Neuropsychology*. 2009; 23:746–758. [PubMed: 19899833]
- Duff K, Beglinger LJ, Schultz SK, Moser DJ, McCaffrey RJ, Haase RF, Paulsen JS. Practice effects in the prediction of long-term cognitive outcome in three patient samples: A novel prognostic index. *Archives of Clinical Neuropsychology*. 2007; 22:15–24. [PubMed: 17142007]
- Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*. 1975; 12:189–198. [PubMed: 1202204]

- Fozard JL, Vercryssen M, Reynolds SL, Hancock PA, Quilter RE. Age differences and changes in reaction time: The Baltimore Longitudinal Study of Aging. *Journal of Gerontology*. 1994; 49:P179–P189. [PubMed: 8014399]
- de Frias CM, Dixon RA, Fisher N, Camicioli R. Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults. *Neuropsychologia*. 2007; 45:2499–2507. [PubMed: 17507058]
- Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. *Neurology*. 2006; 67:1605–1611. [PubMed: 17101891]
- Ganchar, ST. Scales for the assessment of movement disorders. In: Herndon, RM., editor. *Handbook of neurologic rating scales*. New York: Demos Vermande; 1997. p. 81-106.
- Garrett DD, Kovacevic N, McIntosh AR, Grady CL. Blood oxygen level-dependent signal variability is more than just noise. *The Journal of Neuroscience*. 2010; 30:4914–4921. [PubMed: 20371811]
- Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 1988; 51:745–752.
- Goetz CG, LeWitt PA, Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: Newly available teaching program. *Movement Disorders*. 2003; 18:1455–1458. [PubMed: 14673881]
- Gorus E, De Raedt R, Lambert M, Lemper JC, Mets T. Reaction times and performance variability in normal aging, mild cognitive impairment, and Alzheimer's disease. *Journal of Geriatric Psychiatry and Neurology*. 2008; 28:204–218. [PubMed: 18838743]
- Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. *Movement Disorders*. 2004; 19:1043–1049. [PubMed: 15372593]
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology*. 1967; 17:427–442. [PubMed: 6067254]
- Hultsch DF, MacDonald SWS, Hunter MA, Levy-Bencheton J, Strauss E. Intraindividual variability in cognitive performance in the elderly: Comparison of adults with mild dementia, adults with arthritis, and healthy adults. *Neuropsychology*. 2000; 14:588–598. [PubMed: 11055261]
- Hultsch, DF.; Strauss, E.; Hunter, MA.; MacDonald, SWS. Intraindividual variability, cognition, and aging. In: Craik, FIM.; Salthouse, TA., editors. *The handbook of aging and cognition*. 3rd ed.. New York: Psychology Press; 2008. p. 491-556.
- Kelly AMC, Uddin LQ, Biswal BB, Castellanos FX, Milham MP. Competition between functional brain networks mediates behavioral variability. *Neuroimage*. 2008; 39:527–537. [PubMed: 17919929]
- Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Hilker R. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. *Neurology*. 2010; 74:885–892. [PubMed: 20181924]
- Li S, Aggen SH, Nesselrode JR, Baltes PB. Short-term fluctuations in elderly people's sensorimotor functioning predict text and spatial memory performance: The Macarthur Successful Aging Studies. *Gerontology*. 2001; 47:100–116. [PubMed: 11287736]
- Li, S-C.; Lindenberger, U. Cross-level unification: A computational exploration of the link between deterioration of neurotransmitter systems and dedifferentiation of cognitive abilities in old age. In: Nilsson, L-G.; Markowitsch, H., editors. *Cognitive neuroscience and memory*. Toronto: Hogrefe & Huber; 1999. p. 103-146.
- Li S-C, Oertzen Tv, Lindenberger U. A neurocomputational model of stochastic resonance and aging. *Neurocomputing*. 2006; 69:1553–1560.
- Lövdén M, Li S-C, Shing YL, Lindenberger U. Within-person trial-to-trial variability precedes and predicts cognitive decline in old and very old age: Longitudinal data from the Berlin Aging Study. *Neuropsychologia*. 2007; 45:2827–2838. [PubMed: 17575988]
- MacDonald SWS, Hultsch DF, Dixon RA. Performance variability is related to change in cognition: Evidence from the Victoria Longitudinal Study. *Psychology and Aging*. 2003; 18:510–523. [PubMed: 14518812]
- MacDonald SWS, Li S-C, Bäckman L. Neural underpinnings of within-person variability in cognitive functioning. *Psychology and Aging*. 2009; 24:792–808. [PubMed: 20025396]

- Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993; 43:2412–2414. [PubMed: 8232972]
- Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. *Journal of the American Geriatrics Society*. 1995; 43:130–137. [PubMed: 7836636]
- Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. *Annals of Neurology*. 1980; 7:486–488. [PubMed: 7396427]
- Stuss DT, Pogue J, Buckle L, Bondar J. Characterization of stability in performance in patients with traumatic brain injury: Variability and consistency on reaction time tests. *Neuropsychology*. 1994; 8:316–324.
- Suchy Y, Kraybill M, Franchow E. Practice effect and beyond: Reaction to novelty as an independent predictor of cognitive decline among older adults. *Journal of the International Neuropsychological Society*. 2011; 17:101–111. [PubMed: 21073771]
- Whitehead BP, Dixon RA, Hultsch DF, MacDonald SWS. Are neurocognitive speed and inconsistency similarly affected in Type 2 diabetes? *Journal of Clinical and Experimental Neuropsychology*. 2011; 33:647–657. [PubMed: 21416426]
- Yesavage JA. Geriatric Depression Scale. *Psychopharmacology Bulletin*. 1988; 24:709–711. [PubMed: 3249773]

Figure 1.

Over the 18-month interval, the PD and PDID groups performed slower on average on RT whereas healthy older adults improved.

Figure 2.

The PD group performed faster on average with increasing task complexity whereas the PDID group performed slower.

Figure 3. PDID patients became more inconsistent over time whereas the PD patients and healthy older adults remained at baseline levels of inconsistency. RT IIV = reaction time intraindividual variability, or individual standard deviation.

Figure 4. PDID patients' and healthy older adults' level of inconsistency averaged over time was moderated by task complexity. RT IIV = reaction time intraindividual variability, or individual standard deviation.

Table 1

Raw mean RT and standard deviation values (in ms) for each group by wave of measurement

Variables	Group					
	Controls		PD patients		PDID patients	
	T1 (n=42)	T2 (n=42)	T1 (n=28)	T2 (n=27)	T1 (n=20)	T2 (n=18)
SRT	355.12 (63.25)	338.77 (56.04)	376.53 (74.25)	392.29 (102.54)	389.15 (88.96)	419.78 (76.71)
CRT	870.68 (125.57)	856.80 (103.11)	920.30 (125.73)	966.09 (133.67)	1137.48 (185.45)	1200.38 (208.92)

Note. Values in parentheses are standard deviations.

Table 2
Cognitive impairment and health status of the PD patients and controls who participated over the 18-month period

Variables	Group					
	Controls		PD patients		PDID patients	
	T1 n = 47	T2 n = 43	T1 n = 28	T2 n = 28	T1 n = 20	T2 n = 20
Age	71.64 (5.02) Range: 65–84	72.98 (5.01) Range: 67–85	69.81 (3.70) Range: 65–77	71.36 (3.71) Range: 67–79	73.99 (5.11) Range: 66–84	75.50 (5.09) Range: 68–86
Education	15.23 (3.51) Range: 8–23	15.23 (3.51) Range: 8–23	14.64 (3.38) Range: 10–25	14.64 (3.38) Range: 10–25	13.40 (2.11) Range: 9–16	13.40 (2.11) Range: 9–16
MMSE	28.48 (1.61)	27.98 (1.55)	28.75 (1.35)	28.00 (1.28)	27.15 (1.73)	25.25 (4.33)
Dementia Rating Scale (DRS)	138.50 (3.64)	139.14 (3.42)	138.04 (3.77)	138.68 (2.92)	134.75 (4.95)	131.05 (12.25)
Cumulative Illness Rating Scale (CIRS)	18.61 (2.55)	19.52 (2.80)	18.93 (2.67)	19.54 (2.46)	19.90 (2.97)	21.65 (3.34)
Hachinski Ischemic Score	.41 (.73)	.83 (1.20)	.71 (.98)	1.07 (1.65)	.75 (1.21)	1.55 (1.99)
National Adult Reading Test-Revised (NART-R)	109.44 (7.98)	111.15 (8.56)	106.77 (8.18)	108.21 (8.33)	105.45 (5.32)	107.16 (6.98)
Geriatric Depression Scale (GDS)	.66 (1.01)	.67 (.98)	1.39 (1.55)	1.79 (1.95)	2.55 (3.14)	3.00 (2.85)
Frontal Assessment Battery (FAB)	15.16 (1.68)	15.74 (1.70)	15.18 (1.95)	15.18 (2.34)	13.65 (2.16)	12.80 (2.55)
<i>Unified PD Rating Scales (UPDRS)</i>						
Subscale I: Mentation, behavior and mood	.34 (.57)	.40 (.70)	1.11 (1.10)	1.32 (1.06)	1.30 (1.17)	2.05 (2.44)
Subscale II: Activities of Daily Living	.80 (1.42)	.88 (1.26)	7.07 (4.54)	7.04 (3.95)	11.35 (7.51)	12.20 (7.36)
Subscale III: Motor exam	2.16 (3.13)	1.79 (2.28)	15.43 (6.76)	14.71 (8.48)	18.15 (9.55)	20.85 (10.79)

Notes. Values in parentheses are standard deviations. The group by time interactions were not statistically significant based on a MANOVA.

T1= Time 1, T2 = Time 2.

Table 3

Sensitivity and specificity rates of logistic regression models for predicted probability values of .50 for each group pairing

RT (in difference scores)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
PD vs. C				
RT average	95	97	95	97
RT IIV	24	92	63	69
PDID vs. C				
RT average	71	97	91	90
RT IIV	43	95	75	82
PDID vs. PD				
RT average	36	90	71	68
RT IIV	43	86	67	86

Notes. C = controls; PPV = positive predictive value; NPV = negative predictive value.